Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Recurrent CDI in Pediatric and Young Adult Patients
NCT02134392Phase 1Unknown
- Start
- Dec 2013
- Primary completion
- Jan 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic fecal microbiota in Clostridium difficile infection (CDI). Primary endpoint: Resolution of Clostridium difficile infection at 6 months. Status: unknown.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02134392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134392.